Analyst Rating Update on Pernix Therapeutics Holdings (PTX)

Pernix Therapeutics Holdings (NASDAQ:PTX) : The consensus on Pernix Therapeutics Holdings (NASDAQ:PTX) based on 3 analyst recommendation on the company stock is 2.33, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 5 which endorses a Strong Sell on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Pernix Therapeutics Holdings (NASDAQ:PTX) : The highest short term price target forecast on Pernix Therapeutics Holdings (NASDAQ:PTX) is $10 and the lowest target price is $3. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $6.5 with a standard deviation of $4.95.

For the current week, the company shares have a recommendation consensus of Buy.

Pernix Therapeutics Holdings (NASDAQ:PTX): stock turned positive on Tuesday. Though the stock opened at $0.469, the bulls momentum made the stock top out at $0.4798 level for the day. The stock recorded a low of $0.4494 and closed the trading day at $0.465, in the green by 1.53%. The total traded volume for the day was 2,246,920. The stock had closed at $0.458 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc., Siegel Barry J, had purchased 5,000 shares in a transaction dated on August 19, 2015. The transaction was executed at $4.49 per share with total amount equaling $22,450.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.